Revenue climbed 13.0% year-over-year to $717.3M in 2026Q3 with operating margin of 7.0% and diluted EPS of $0.83, though SG&A consuming roughly 20.8% of revenue continues to limit operating leverage.
AMN Healthcare Services, Inc. (AMN) annual income statement — 26-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 |
|---|
| Sales/Revenue | 3.52B | 2.73B | 2.98B | 3.79B | 5.24B | 3.98B | 2.39B | 2.22B | 2.14B | 1.99B | 1.9B | 1.46B | 1.04B | 1.01B | 953.95M | 887.47M | 689.22M | 759.79M | 1.22B | 1.16B | 1.08B | 705.84M | 629.02M | 714.21M | 775.68M | 517.79M | 230.77M |
| Revenue Growth % | 29.45% | -8.49% | -21.26% | -27.73% | 31.6% | 66.45% | 7.72% | 4.03% | 7.42% | 4.53% | 30.02% | 41.22% | 2.39% | 6.07% | 7.49% | 28.76% | -9.29% | -37.58% | 4.57% | 7.61% | 53.25% | 12.21% | -11.93% | -7.93% | 49.81% | 124.38% | - |
| Cost of Goods Sold | 2.52B | 1.96B | 2.06B | 2.54B | 3.53B | 2.67B | 1.6B | 1.48B | 1.44B | 1.34B | 1.28B | 993.7M | 719.91M | 714.54M | 683.55M | 638.15M | 497.69M | 555.37M | 900.21M | 860.86M | 792.41M | 535.61M | 484.65M | 552.05M | 586.9M | 388.28M | 170.61M |
| COGS % of Revenue | - | 71.65% | 69.19% | 67.02% | 67.26% | 67.13% | 66.92% | 66.54% | 67.4% | 67.59% | 67.42% | 67.92% | 69.49% | 70.62% | 71.66% | 71.91% | 72.21% | 73.1% | 73.96% | 73.96% | 73.26% | 75.88% | 77.05% | 77.3% | 75.66% | 74.99% | 73.93% |
| Gross Profit | 998.97M | 774.06M | 919.38M | 1.25B | 1.72B | 1.31B | 791.78M | 743.47M | 696.38M | 644.42M | 619.72M | 469.36M | 316.12M | 297.28M | 270.4M | 249.32M | 191.53M | 204.42M | 316.99M | 303.17M | 289.29M | 170.24M | 144.36M | 162.16M | 188.78M | 129.51M | 60.16M |
| Gross Margin % | 28.4% | 28.35% | 30.81% | 32.98% | 32.74% | 32.87% | 33.08% | 33.46% | 32.6% | 32.41% | 32.58% | 32.08% | 30.51% | 29.38% | 28.34% | 28.09% | 27.79% | 26.9% | 26.04% | 26.04% | 26.74% | 24.12% | 22.95% | 22.7% | 24.34% | 25.01% | 26.07% |
| Gross Profit Growth % | - | -15.81% | -26.43% | -27.21% | 31.08% | 65.4% | 6.5% | 6.76% | 8.06% | 3.98% | 32.04% | 48.48% | 6.34% | 9.94% | 8.45% | 30.18% | -6.31% | -35.51% | 4.56% | 4.8% | 69.93% | 17.92% | -10.97% | -14.1% | 45.77% | 115.28% | - |
| Operating Expenses | 796.21M | 740.89M | 1.02B | 911.15M | 1.07B | 831.6M | 642.51M | 566.55M | 493.56M | 431.98M | 428.09M | 340.48M | 248.21M | 231.78M | 217.06M | 211.67M | 183.21M | 171.05M | 490.21M | 230.82M | 215.82M | 123.5M | 108.02M | 98.19M | 102.52M | 113.03M | 57.91M |
| OpEx % of Revenue | - | 27.13% | 34.25% | 24.05% | 20.4% | 20.87% | 26.84% | 25.5% | 23.11% | 21.72% | 22.5% | 23.27% | 23.96% | 22.91% | 22.75% | 23.85% | 26.58% | 22.51% | 40.27% | 19.83% | 19.95% | 17.5% | 17.17% | 13.75% | 13.22% | 21.83% | 25.09% |
| Selling, General & Admin | 667.2M | 593.02M | 632.49M | 756.24M | 936.58M | 730.45M | 549.75M | 508.03M | 452.32M | 399.7M | 398.47M | 319.53M | 232.22M | 218.23M | 202.9M | 195.35M | 168.13M | 157.24M | 230.66M | 218.25M | 205.5M | 117.33M | 102.19M | 93.37M | 98.68M | 103.36M | 54.61M |
| SG&A % of Revenue | - | 21.72% | 21.2% | 19.96% | 17.86% | 18.33% | 22.97% | 22.86% | 21.18% | 20.1% | 20.95% | 21.84% | 22.41% | 21.57% | 21.27% | 22.01% | 24.39% | 20.7% | 18.95% | 18.75% | 19% | 16.62% | 16.25% | 13.07% | 12.72% | 19.96% | 23.66% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 4M | 147.87M | 389.56M | 154.91M | 133.01M | 101.15M | 92.77M | 58.52M | 41.24M | 32.28M | 29.62M | 20.95M | 15.99M | 13.54M | 14.15M | 16.32M | 15.08M | 13.81M | 14.44M | 12.57M | 10.32M | 6.18M | 5.84M | 4.82M | 3.84M | 9.67M | 3.3M |
| Operating Income | 202.76M | 33.17M | -102.67M | 338.43M | 647.1M | 478M | 149.26M | 176.91M | 202.83M | 212.44M | 191.63M | 128.88M | 67.9M | 65.5M | 53.34M | 37.65M | -42.52M | -153.61M | 71.89M | 72.34M | 73.46M | 46.73M | 36.34M | 63.96M | 86.27M | 16.48M | 2.25M |
| Operating Margin % | 5.76% | 1.21% | -3.44% | 8.93% | 12.34% | 12% | 6.24% | 7.96% | 9.5% | 10.68% | 10.07% | 8.81% | 6.55% | 6.47% | 5.59% | 4.24% | -6.17% | -20.22% | 5.91% | 6.21% | 6.79% | 6.62% | 5.78% | 8.96% | 11.12% | 3.18% | 0.97% |
| Operating Income Growth % | - | 132.3% | -130.34% | -47.7% | 35.38% | 220.23% | -15.63% | -12.78% | -4.52% | 10.86% | 48.69% | 89.8% | 3.67% | 22.8% | 41.69% | 188.54% | 72.32% | -313.66% | -0.62% | -1.53% | 57.21% | 28.59% | -43.19% | -25.85% | 423.52% | 633.01% | - |
| EBITDA | 341.56M | 189.77M | 71.11M | 499.36M | 784.21M | 581.7M | 243.45M | 235.44M | 244.06M | 244.72M | 221.25M | 149.83M | 83.9M | 79.05M | 67.49M | 53.97M | -27.43M | -139.8M | 86.33M | 84.02M | 83.79M | 52.91M | 42.18M | 68.78M | 90.1M | 24.19M | 5.55M |
| EBITDA Margin % | 9.71% | 6.95% | 2.38% | 13.18% | 14.96% | 14.6% | 10.17% | 10.6% | 11.43% | 12.31% | 11.63% | 10.24% | 8.1% | 7.81% | 7.08% | 6.08% | -3.98% | -18.4% | 7.09% | 7.22% | 7.75% | 7.5% | 6.71% | 9.63% | 11.62% | 4.67% | 2.41% |
| EBITDA Growth % | 336.41% | 166.88% | -85.76% | -36.32% | 34.82% | 138.94% | 3.41% | -3.54% | -0.27% | 10.61% | 47.67% | 78.59% | 6.13% | 17.12% | 25.05% | 296.73% | 80.38% | -261.93% | 2.76% | 0.27% | 58.36% | 25.45% | -38.68% | -23.66% | 272.47% | 335.8% | - |
| D&A (Non-Cash Add-back) | 138.81M | 156.6M | 173.78M | 160.93M | 137.11M | 103.7M | 94.19M | 58.52M | 41.24M | 32.28M | 29.62M | 20.95M | 15.99M | 13.54M | 14.15M | 16.32M | 15.08M | 13.81M | 14.44M | 11.67M | 10.32M | 6.18M | 5.84M | 4.82M | 3.84M | 7.71M | 3.3M |
| EBIT | 202.71M | -55.47M | -102.67M | 338.43M | 647.1M | 478M | 149.26M | 176.91M | 202.83M | 212.44M | 191.63M | 128.88M | 64.79M | 65.5M | 43.53M | 37.65M | -43.78M | -153.61M | 71.89M | 72.34M | 73.46M | 45.53M | 36.34M | 63.96M | 86.27M | 16.48M | 2.25M |
| Net Interest Income | -33.33M | -45.59M | -69.9M | -54.14M | -40.4M | -34.08M | -57.74M | -28.43M | -16.14M | -19.68M | -15.46M | -7.79M | -9.24M | -9.66M | -26.02M | -23.73M | -19.76M | -11.96M | -10.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 33.33M | 45.59M | 69.9M | 54.14M | 40.4M | 34.08M | 57.74M | 28.43M | 16.14M | 19.68M | 15.46M | 7.79M | 9.24M | 9.66M | 26.02M | 23.73M | 19.77M | 11.96M | 10.69M | 12.46M | 16.7M | 9.56M | 8.44M | 2.3M | 0 | 0 | 0 |
| Other Income/Expense | -33.37M | -134.23M | -69.9M | -54.14M | -40.4M | -34.08M | -57.74M | -28.43M | -16.14M | -19.68M | -15.46M | -7.79M | -9.24M | -9.66M | -26.02M | -23.73M | -19.77M | -11.96M | -10.69M | -11.56M | -16.7M | -9.56M | -8.44M | -2.3M | 343K | -13.93M | -10.01M |
| Pretax Income | 169.38M | -101.06M | -172.57M | 284.29M | 606.7M | 443.92M | 91.52M | 148.49M | 186.69M | 192.76M | 176.17M | 121.09M | 58.67M | 55.84M | 27.32M | 13.92M | -62.29M | -165.56M | 61.2M | 60.78M | 56.77M | 37.16M | 27.9M | 61.66M | 86.61M | 2.54M | -7.76M |
| Pretax Margin % | 4.82% | -3.7% | -5.78% | 7.5% | 11.57% | 11.14% | 3.82% | 6.68% | 8.74% | 9.69% | 9.26% | 8.28% | 5.66% | 5.52% | 2.86% | 1.57% | -9.04% | -21.79% | 5.03% | 5.22% | 5.25% | 5.27% | 4.44% | 8.63% | 11.17% | 0.49% | -3.36% |
| Income Tax | 60.36M | -5.36M | -25.59M | 73.61M | 162.65M | 116.53M | 20.86M | 34.5M | 44.94M | 60.2M | 70.33M | 39.2M | 25.45M | 22.9M | 11.01M | 8.9M | -10.3M | -43.39M | 26.85M | 24.25M | 21.68M | 14.93M | 10.55M | 23.87M | 34.25M | 1.48M | -2.56M |
| Effective Tax Rate % | 35.64% | 5.3% | 14.83% | 25.89% | 26.81% | 26.25% | 22.79% | 23.23% | 24.07% | 31.23% | 39.92% | 32.37% | 43.38% | 41.02% | 40.3% | 63.97% | 16.53% | 26.21% | 43.86% | 39.9% | 38.18% | 40.17% | 37.83% | 38.71% | 39.55% | 58% | 33% |
| Net Income | 109.02M | -95.7M | -146.98M | 210.68M | 444.05M | 327.39M | 70.67M | 113.99M | 141.74M | 132.56M | 105.84M | 81.89M | 33.22M | 32.93M | 17.14M | -26.27M | -51.99M | -122.18M | 34.36M | 36.53M | 35.09M | 22.23M | 17.35M | 37.79M | 52.36M | -4.39M | -5.2M |
| Net Margin % | 3.1% | -3.5% | -4.93% | 5.56% | 8.47% | 8.22% | 2.95% | 5.13% | 6.64% | 6.67% | 5.56% | 5.6% | 3.21% | 3.25% | 1.8% | -2.96% | -7.54% | -16.08% | 2.82% | 3.14% | 3.24% | 3.15% | 2.76% | 5.29% | 6.75% | -0.85% | -2.25% |
| Net Income Growth % | 139.57% | 34.89% | -169.76% | -52.56% | 35.63% | 363.3% | -38.01% | -19.58% | 6.93% | 25.25% | 29.24% | 146.53% | 0.86% | 92.19% | 165.24% | 49.48% | 57.45% | -455.61% | -5.95% | 4.11% | 57.83% | 28.18% | -54.1% | -27.82% | 1293.71% | 15.62% | - |
| Net Income (Continuing) | 109.02M | -95.7M | -146.98M | 210.68M | 444.05M | 327.39M | 70.67M | 113.99M | 141.74M | 132.56M | 105.84M | 81.89M | 33.22M | 32.93M | 16.31M | 5.02M | -51.99M | -122.18M | 34.36M | 36.53M | 35.09M | 22.23M | 17.35M | 37.79M | 52.36M | 1.07M | -5.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 2.71 | -2.48 | -3.85 | 5.36 | 9.90 | 6.81 | 1.48 | 2.40 | 2.91 | 2.68 | 2.15 | 1.68 | 0.69 | 0.69 | 0.37 | -0.57 | -1.49 | -3.75 | 1.02 | 1.04 | 1.02 | 0.69 | 0.55 | 0.95 | 1.12 | -0.14 | -0.23 |
| EPS Growth % | 138.26% | 35.58% | -171.83% | -45.86% | 45.37% | 360.14% | -38.33% | -17.53% | 8.58% | 24.65% | 27.98% | 143.48% | 0% | 86.49% | 164.91% | 61.75% | 60.27% | -467.65% | -1.92% | 1.96% | 47.83% | 25.45% | -42.11% | -15.18% | 900% | 39.13% | - |
| EPS (Basic) | - | -2.48 | -3.85 | 5.38 | 9.96 | 6.87 | 1.49 | 2.44 | 2.99 | 2.77 | 2.21 | 1.72 | 0.71 | 0.72 | 0.38 | -0.66 | -1.49 | -3.75 | 1.03 | 1.06 | 1.07 | 0.76 | 0.61 | 1.04 | 1.23 | -0.14 | -0.23 |
| Diluted Shares Outstanding | 40.16M | 38.52M | 38.19M | 39.34M | 44.87M | 48.05M | 47.69M | 47.59M | 48.67M | 49.43M | 49.27M | 48.84M | 48.09M | 47.79M | 46.71M | 45.95M | 34.84M | 32.62M | 33.81M | 34.88M | 34.5M | 32.12M | 31.37M | 39.78M | 46.8M | 30.64M | 22.5M |
| Basic Shares Outstanding | 39.11M | 38.52M | 38.19M | 39.17M | 44.59M | 47.69M | 47.42M | 46.7M | 47.37M | 47.81M | 47.95M | 47.52M | 46.5M | 45.96M | 41.63M | 39.91M | 34.84M | 32.62M | 33.38M | 34.38M | 32.66M | 29.13M | 28.25M | 36.46M | 42.53M | 30.64M | 22.5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying AMN stock.
For fiscal year 2025, AMN Healthcare Services, Inc. (AMN) reported total revenue of $2.73B. This represents a 1083.2% increase compared to $230.8M in 2000.
AMN Healthcare Services, Inc. (AMN) reported a net loss of $95.7M for the fiscal year ending 2025.
AMN Healthcare Services, Inc. (AMN) reported an operating income of $33.2M, resulting in an operating profit margin of 1.2%. This margin reflects the operational efficiency of the business before interest and taxes.
AMN Healthcare Services, Inc. (AMN) generated $774.1M in gross profit for the year, representing a gross profit margin of 28.3%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Hospital labor demand volatility
Metrics are mathematically derived from official filings.
Revenue Rebounds After Mid-Cycle Trough
According to reported quarterly figures, AMN's revenue climbed from $634.5M in 2025Q3 to $717.3M in 2026Q3, a 13.0% year-over-year gain that suggests demand has begun to recover from its post-pandemic normalization trough.
The 2026Q3 top-line improvement appears driven by nursing and allied staffing demand, which management attributes to demand strengthening into October. However, the -8.49% trailing decline indicates the rebound is recent and not yet established as a durable trend. Investors should monitor whether sequential growth persists across the next two quarters before treating the recovery as structural.
Gross Margin Recovers Within Narrow Band
Based on EDBL-style reported figures, AMN's gross margin improved to 31.9% in 2026Q3 from 26.1% in 2025Q4, with the trailing range suggesting pricing spreads remain sensitive to clinician pay pressure.
The margin fluctuation across the ten-quarter window indicates that the bill-pay spread is the dominant variable in AMN's gross profit, rather than a fixed structural advantage. The 2026Q3 expansion may reflect favorable mix toward higher-margin Technology and Workforce revenue, though the reported data does not isolate this contribution. Sustained margins above 30% would warrant closer examination of whether pricing power is improving or whether the result is cyclical.
Operating Leverage Remains Constrained
As reported in financial statements, AMN's SG&A of $149.3M in 2026Q3 consumed roughly 20.8% of revenue, leaving operating margin at 7.0%, which suggests overhead remains a meaningful drag on incremental profitability.
Operating income of $50.5M in 2026Q3 versus $8.4M a year earlier reflects some scaling, but SG&A grew broadly in line with revenue, limiting the operating leverage effect. The quarterly operating margin has oscillated between roughly 1% and 8% outside of impairment-affected periods, which may indicate a cost base that has not yet been right-sized to current demand. Continued SG&A discipline will be essential for margin expansion.
EPS Beat Diverges From Net Margin
Based on reported figures, AMN's 2026Q3 diluted EPS of $0.83 contrasts with a trailing net margin still in negative territory, suggesting the headline earnings improvement may rely on items outside core operations.
A $33.4M net income against $50.5M operating income implies meaningful below-the-line charges, including interest expense on elevated leverage. The trailing ROE of -14.2% and Debt/Equity of 1.25 reinforce that earnings have not yet translated into sustained equity value creation. Investors should verify earnings quality against the cash flow statement before extrapolating the quarterly EPS result.
Guidance Cut Tempers Quarterly Optimism
According to management's lowered forward guidance of $655M to $670M, the strong 2026Q3 quarter may not signal sustained top-line momentum, which warrants scrutiny of how durable the demand recovery truly is.
The downward revision in guidance, despite a quarter of positive demand commentary, suggests management is less confident in near-term visibility than the EPS result implies. If labor disruption revenue or other non-recurring contributions drove 2026Q3, the run rate may normalize sharply. Short-sellers would likely point to the persistent negative net margin and elevated leverage as evidence that the recovery is fragile.